Prequel® Prenatal Screen with AMPLIFY™ Technology

Guide your patients with genetic insights during a special time in their life: their pregnancy.

Get started today

Why Prequel?

The Prequel® Prenatal Screen is designed to provide individualized insights for each patient, so you can seamlessly and consistently incorporate prenatal genetic screening into your practice. This means more of your patients will benefit from valuable information that can make a difference in health outcomes for families.

Deliver equity of care for every patient

Prequel with AMPLIFY delivers results to 99.9% of patients on the first draw regardless of ancestry or body mass index (BMI).1 Why is that important?

  • 1 out of 2 pregnant patients presents to their OBGYN with high BMI.2
  • With regard to noninvasive prenatal screening (NIPS) via cell-free DNA (cfDNA), high BMI is associated with low fetal fraction which may result in up to a 24.3% failure rate in cell-free DNA (cfDNA) non-invasive prenatal screening (NIPS).3 To circumvent the association with lower fetal fraction, some clinicians delay screening their patients with high BMI so that the fetal fraction would naturally be higher later in pregnancy; however, this protocol variation creates an inequity in care by allowing less time for patients with high BMI to consider pregnancy management options in the event of a high-risk result.
  • Since BMI is also correlated more closely with certain ancestries,3 delaying screening according to a patient’s BMI to ensure a higher fetal fraction means some patients have less time to consider pregnancy management options in the case of a high-risk result.
  • Sample failures may result in increased patient anxiety, increased staff time managing the screen, and less time for pregnancy management in the case of high-risk results.4
  • Prequel enables screening of all patients at 10 weeks, even those with high BMI, helping you partner with every patient in managing their pregnancy journey.

Early insights

Watch this patient story to hear how noninvasive prenatal screening can give a patient like Hannah, early insights into her pregnancy to help prepare her family.

Prepare with timely and actionable insights

Screening at 10 weeks gives you and your patient time to explore different options such as:

  • Pursuing diagnostic testing
  • Speaking to a specialist
  • Finding the right facility to deliver
  • Exploring support groups

Take action today

Meet

Meet with your patient to discuss non-invasive prenatal screening.

Order

Submit the completed Test Request Form (TRF) and sample.

Receive

Receive Prequel results in approximately 7-10 days.

Review

Review results with patient.

Educate

Refer patients to schedule a consultation with Myriad’s Certified Genetic Counselors.

About Prequel

Myriad provides user-friendly, clear results, as well as access to genetic counselors for patient education pre-screening and post-results.

The Prequel® Prenatal Screen with AMPLIFY™ technology is a non-invasive prenatal screen that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for common chromosome abnormalities, such as Down Syndrome (Trisomy 21), Turner Syndrome (Trisomy 18), and Patau Syndrome (Trisomy 13).

cfDNA screening has been shown to be superior to methods that use maternal age, ultrasound, and serum screening6, and results in a lower false-positive rate and false-negative rate. That translates to a lower chance of needing a repeat test or an invasive diagnostic procedure. We use advanced science and technology that works for any pregnancy regardless of age, including those with twin and IVF pregnancies.

The Prequel Prenatal Screen can be ordered together with the Foresight® Carrier Screen and offered to any pregnant person. Prequel can provide individual fetal sex information for twins, in addition to singleton pregnancy.

The mid adult female doctor reviews her patient's records on her computer in her office.

Screening options

Included with every screen: Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), Trisomy 13 (Patau syndrome)

Optional panels:

  • Sex Chromosome Analysis (SCA): Genetic sex prediction (includes twin pregnancies), Monosomy X (Turner syndrome), Klinefelter syndrome (XXY), Trisomy X (XXX), XYY syndrome
  • Microdeletions: 22q11 deletion (DiGeorge syndrome), 1p36 deletion syndrome, 15q11 deletions (Angelman or Prader-Willi syndrome), 4p deletion (Wolf-Hirschhorn syndrome), 5p deletion (Cri-du-Chat syndrome)
  • Expanded Aneuploidy Analysis (EAA): Includes analysis of all chromosomes, placental insufficiency (e.g. growth restriction, stillbirth), uniparental Disomy Syndromes (e.g. Prader-Willi), Fetal Syndromes (e.g. Trisomy 8, Trisomy 22)
View full list

Supporting services with Myriad Complete™

Myriad offers the following through Myriad Complete to help seamlessly integrate testing and screening into your practice.

Education

We provide resources to help educate your patients about Myriad products.

Access

We offer a comprehensive program to make genetic products accessible for more of your patients.

Results

We deliver screening and testing results effectively and thoroughly so you can focus on care plans.

Consults

We provide consults from patient educators, who are genetic counselors, tailored to help address any questions your patients may have.

Learn more Virtual testing options

References

  1. Hancock S, Ben-Shachar R, Adusei C, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020;56(3):422-430. doi:10.1002/uog.21904
  2. Deputy NP, Dub B, Sharma AJ. Prevalence and Trends in Prepregnancy Normal Weight – 48 States, New York City, and District of Columbia, 2011-2015. MMWR Morb Mortal Wkly Rep. 2018;66(51-52):1402-1407. Published 2018 Jan 5. doi:10.15585/mmwr.mm665152a3
  3. Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenat Diagn. 2020;40(3):333-341. doi:10.1002/pd.5603
  4. Artieri CG, Haverty C, Evans EA, et al. Noninvasive prenatal screening at low fetal fraction: comparing whole-genome sequencing and single-nucleotide polymorphism methods. Prenat Diagn. 2017;37(5):482-490. doi:10.1002/pd.5036
  5. Norton, M. et al Cell free DNA analysis for noninvasive examination of trisomy. The New England Journal of Medicine April 2015; 372: 1589-1597
  6. Fairbrother G, Burigo J, Sharon T, Song K. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. J Matern Fetal Neonatal Med. 2016;29(7):1160-1164. doi:10.3109/14767058.2015.1038703